Rivaroxaban in Idiopathic Membranous Nephropathy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Rivaroxaban in Idiopathic Membranous Nephropathy — Stella

Home/Idiopathic Membranous Nephropathy/

View on ClinicalTrials.gov

Recruiting

Back to Idiopathic Membranous Nephropathy trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

China

Beijing Friedship Hospital, Beijing, Beijing Municipality

Key details

Phase

Post-approval study

Sponsor

Beijing Friendship Hospital

Enrollment target

~134 participants

Started

January 2024

Primary completion

December 2026

Age range

18 Years – 80 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.